Flies as the ointment Drosophila modeling to enhance drug discovery

被引:19
|
作者
Bell, Aaron J. [2 ]
McBride, Sean M. J. [2 ]
Dockendorff, Thomas C. [1 ]
机构
[1] Univ Tennessee, Dept Biochem & Cellular & Mol Biol, Knoxville, TN 37996 USA
[2] Albert Einstein Coll Med, Dept Mol Pharmacol, Div Mol Cardiol, Bronx, NY 10467 USA
关键词
Drosophila; drug discovery; disease modeling; neurodegeneration; mental retardation; FRAGILE-X-SYNDROME; HISTONE DEACETYLASE INHIBITORS; FAMILIAL ALZHEIMERS-DISEASE; ELEGANS VULVAR INDUCTION; MENTAL-RETARDATION; ALPHA-SYNUCLEIN; GENE-EXPRESSION; MOUSE MODEL; DEPENDENT NEURODEGENERATION; HOMOLOGOUS RECOMBINATION;
D O I
10.4161/fly.3.1.7774
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Development of a drug and its safe therapeutic application necessitates using animal models for testing purposes. While testing with mammalian models is essential prior to approval for human trials, the use of invertebrate animal models that are amenable to molecular genetic manipulations provide experimental and biological advantages that can streamline the discovery and testing process. Among the benefits of a genetics-based approach is the ability to screen for genes/proteins that may be novel drug targets, and the expedited development of genetic backgrounds that more accurately reflect a specific disease state. An invertebrate model may provide a more robust phenotype for screening, a situation that may arise when there is unanticipated genetic redundancy present in the mammalian model. Finally, the comparatively short generation time and fecundity of invertebrate models allows for increased experimental throughput. Together, these factors may contribute towards savings in time and cost during the drug discovery process.
引用
收藏
页码:39 / 49
页数:11
相关论文
共 50 条
  • [2] Drug discovery and chemical probing in Drosophila
    Millet-Boureima, Cassandra
    Selber-Hnatiw, Susannah
    Gamberi, Chiara
    GENOME, 2021, 64 (02) : 147 - 159
  • [3] Fruitful research: drug target discovery for neurodegenerative diseases in Drosophila
    Konsolaki, Mary
    EXPERT OPINION ON DRUG DISCOVERY, 2013, 8 (12) : 1503 - 1513
  • [4] Drug Discovery in Fish, Flies, and Worms
    Strange, Kevin
    ILAR JOURNAL, 2016, 57 (02) : 133 - 143
  • [5] An assessment of the translational relevance of Drosophila in drug discovery
    Papanikolopoulou, Katerina
    Mudher, Amrit
    Skoulakis, Efthimios
    EXPERT OPINION ON DRUG DISCOVERY, 2019, 14 (03) : 303 - 313
  • [6] A Drosophila Based Cancer Drug Discovery Framework
    Bangi, Erdem
    DROSOPHILA MODEL IN CANCER, 2019, 1167 : 237 - 248
  • [7] Modeling Parkinson's disease in adult Drosophila
    Dabool, Lital
    Juravlev, Liza
    Hakim-Mishnaevski, Ketty
    Kurant, Estee
    JOURNAL OF NEUROSCIENCE METHODS, 2019, 311 : 89 - 94
  • [8] Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery
    Corti, Stefania
    Faravelli, Irene
    Cardano, Marina
    Conti, Luciano
    EXPERT OPINION ON DRUG DISCOVERY, 2015, 10 (06) : 615 - 629
  • [9] Modeling schizophrenia in flies
    Furukubo-Tokunaga, Katsuo
    GENETIC MODELS OF SCHIZOPHRENIA, 2009, 179 : 107 - 115
  • [10] Human Disease Models in Drosophila melanogaster and the Role of the Fly in Therapeutic Drug Discovery
    Pandey, Udai Bhan
    Nichols, Charles D.
    PHARMACOLOGICAL REVIEWS, 2011, 63 (02) : 411 - 436